Rituximab use in the COVID-19 era: Striking the right balance | Sebastian Sattui and David Jayne 

With rituximab-treated patients having an elevated risk for severe COVID-19 and a reduced likelihood of responding to vaccines, Sebastian Sattui and David Jayne discuss how these challenges can be addressed and explore the future role of the drug for the treatment of rheumatic diseases.
00:00 Introduction to the speakers
00:26 The current situation with rituximab and COVID-19
01:32 Considerations for patients with rheumatoid arthritis
02:46 Considerations for patients with ANCA-associated vasculitis
06:02 Optimizing response to vaccines
07:38 Other interventions to reduce COVID-19 risk or severity
09:40 Balancing disease control and infection risk
11:50 Concluding remarks
View more on Medicine Matters rheumatology: bit.ly/2U6Vxhi